Breaking News

Vectura, Inspira Partner to Develop Inhaled COVID Treatment

Further testing and development work to prepare for Phase 1 studies using its FOX vibrating mesh nebulizer to deliver IPX formulations.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Vectura Group plc, an inhalation CDMO, and Inspira Pharmaceuticals, a UK-based company focused on developing therapies for respiratory and infectious diseases, entered an agreement to develop an inhaled formulation of Inspira’s lead drug candidate for the potential treatment of COVID-19.   Inspira’s research focuses on proprietary IPX formulations based on processed and purified extracts from a plant source. These extracts contain proteolytic enzymes that have been shown to rapidly inactivate ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters